Review of exclusive enteral therapy in adult Crohn’s disease

Código QR

Review of exclusive enteral therapy in adult Crohn’s disease

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikola Mitrev, Hin Huang, Barbara Hannah, Viraj Chandana Kariyawasam
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/92924197aea8465396ebb294f3c68b88
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn’s disease: a pilot study
por: Konstantinos Gkikas, et al.
Publicado: (2021)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Osama Hamdy, et al.
Publicado: (2021)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Mohammad Shehab, et al.
Publicado: (2021)

Impact of Diagnostic Delay on Disease Course in Pediatric Versus Adult-onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort
por: Alain M. Schoepfer, et al.
Publicado: (2021)

Systematic Therapy for Gastrointestinal Tumors
por: Zhongguang Luo, et al.
Publicado: (2021)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail MH, et al.
Publicado: (2011)

From adolescent PCOS to adult MAFLD: opposing effects of randomised interventions
por: Francis de Zegher, et al.
Publicado: (2021)

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021)

Correction: From adolescent PCOS to adult MAFLD: opposing effects of randomised interventions
Publicado: (2021)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015)

The challenges of implementing evidence‐based therapy for irritable bowel syndrome in Asia
por: Kee‐Huat Chuah, et al.
Publicado: (2021)

Association between hepatic fat and subclinical vascular disease burden in the general population
por: Susanne Rospleszcz, et al.
Publicado: (2021)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Autonomic dysfunction in chronic liver disease
por: Frith J, et al.
Publicado: (2011)

Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
por: XU Jinghang
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
por: WANG Jingyue
Publicado: (2021)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan SV, et al.
Publicado: (2015)

An alternative splicing signature in human Crohn’s disease
por: Daowei Li, et al.
Publicado: (2021)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
por: Bradford V, et al.
Publicado: (2013)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt SJ, et al.
Publicado: (2014)

Implementing Collaborative Care Management of Behavioral Health for Patients with Inflammatory Bowel Disease
por: Christine Beran, et al.
Publicado: (2021)

Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
por: WANG Jing
Publicado: (2021)

Prevalence rate of non-obese fatty liver disease and related influencing factors
por: DENG Jiang
Publicado: (2021)

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
por: Kawanaka M, et al.
Publicado: (2015)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
por: Lau T, et al.
Publicado: (2013)

Cricopharyngeal peroral endoscopic myotomy improves oropharyngeal dysphagia in patients with Parkinson’s disease
por: Peter I. Wu, et al.
Publicado: (2021)

Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma
por: Korenaga K, et al.
Publicado: (2011)

Evaluation of the Clinical Effects and Frequency of MEFV Gene Mutation in Patients with Inflammatory Bowel Disease
por: S. Sahin, et al.
Publicado: (2021)

Meckel’s Diverticulum Diagnosed by Balloon-Assisted Enteroscopy: A Multicenter Report from the Taiwan Association for the Study of Small Intestinal Diseases (TASSID)
por: Jen-Wei Chou, et al.
Publicado: (2021)

DEDICATED PSYCHIATRY CLINIC FOR INFLAMMATORY BOWEL DISEASE PATIENTS HAS A POSITIVE IMPACT ON DEPRESSION SCORES
por: Kaleb Bogale, et al.
Publicado: (2021)

Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study
por: Peter M Irving, et al.
Publicado: (2021)

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease
por: LI Pinhua
Publicado: (2021)

Do gastroenterologists have medical inertia towards coeliac disease? A UK multicentre secondary care study
por: Hugo A Penny, et al.
Publicado: (2021)

A lipid-rich gestational diet predisposes offspring to nonalcoholic fatty liver disease: a potential sequence of events
por: Hughes AN, et al.
Publicado: (2014)

An excerpt of diagnosis, evaluation, and management of ascites and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
por: HU Jiaxuan
Publicado: (2021)

Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease
por: ZHANG Jie
Publicado: (2021)

An excerpt of EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update
por: ZHANG Yue
Publicado: (2021)

Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis
por: Enrique Rodríguez de Santiago, et al.
Publicado: (2021)